Scaffold for subretinal cell transplantation and drug delivery
AssigneesThe Charles Stark Draper Laboratory, Inc., The Schepens Eye Research Institute, Inc.
InventorsSarah L. Tao, Stephen Redenti, Magali Saint-Geniez, Michael Young, Patricia D'Amore
Life of this patent
Estimating the term…
Abstract
The following disclosure provides compositions and methods for the repairing of a diseased or disordered retina, for example, in patients suffering from age-related macular degeneration (AMD).
Claims36
A composition comprising retinal pigment epithelium (RPE) cells adhering to a poly(ε-caprolactone) (PCL) membrane, wherein the PCL membrane comprises a plurality of pores distributed over the PCL membrane, each pore having a diameter of less than 1 micron.
2-3. (canceled)
(canceled)
(canceled)
15-18. (canceled)
(canceled)
25-32. (canceled)
35-37. (canceled)
A method for treating symptoms of a retinal disorder in a patient, comprising:
- implanting a porous poly(ε-caprolactone) (PCL) membrane comprising RPE cells adhered to the PCL membrane into one or both eyes of a patient suffering from a retinal disorder,
- wherein the RPE cells were derived from stem cells isolated from the patient or from a donor, were induced to differentiate into RPE cells, were contacted with the PCL membrane, and were adhered to the membrane.
42-50. (canceled)
A method for manufacturing a composition comprising retinal pigment epithelium (RPE) cells and a porous poly(ε-caprolactone) (PCL) membrane, comprising contacting the RPE cells with a porous PCL membrane, whereby the RPE cells adhere to the porous PCL membrane.
54-60. (canceled)
(canceled)
Dependencies are inferred from the claim text.